114 related articles for article (PubMed ID: 15725690)
21. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
[TBL] [Abstract][Full Text] [Related]
22. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Harris KP; Wheeler DC; Chong CC;
Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
[TBL] [Abstract][Full Text] [Related]
23. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
24. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Milionis HJ; Kakafika AI; Tsouli SG; Athyros VG; Bairaktari ET; Seferiadis KI; Elisaf MS
Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
[TBL] [Abstract][Full Text] [Related]
25. Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease.
Santanu G; Suhrita P; Mookerjee S; Tania K; Mita S; Pramit G; Sharmila G; Miraj M; Debdutta M
Indian Heart J; 2011; 63(5):434-7. PubMed ID: 23550422
[TBL] [Abstract][Full Text] [Related]
26. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
[TBL] [Abstract][Full Text] [Related]
28. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
29. [Atorvastatin . A new generation of hypolipemic agents?].
Azanza JR; Sádaba B; Quetglas EG
Rev Med Univ Navarra; 1998; 42(1):51-5. PubMed ID: 10420957
[No Abstract] [Full Text] [Related]
30. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
31. Effects of atorvastatin on inflammation and oxidative stress.
Sugiyama M; Ohashi M; Takase H; Sato K; Ueda R; Dohi Y
Heart Vessels; 2005 Jul; 20(4):133-6. PubMed ID: 16025360
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
33. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage.
Harangi M; Seres I; Varga Z; Emri G; Szilvássy Z; Paragh G; Remenyik E
Eur J Clin Pharmacol; 2004 Dec; 60(10):685-91. PubMed ID: 15490140
[TBL] [Abstract][Full Text] [Related]
34. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia.
Matafome P; Monteiro P; Nunes E; Louro T; Amaral C; Moedas AR; Gonçalves L; Providência L; Seiça R
Pharmacol Res; 2008; 58(3-4):208-14. PubMed ID: 18692137
[TBL] [Abstract][Full Text] [Related]
36. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
37. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
38. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
39. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
Taylor PJ; Kubler PA; Lynch SV; Allen J; Butler M; Pillans PI
Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751
[TBL] [Abstract][Full Text] [Related]
40. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
